MIAMI and SUNNYVALE, Calif., Oct. 3, 2011 /PRNewswire/ -- American Society for Radiation Oncology (ASTRO) 53rd Annual Meeting --Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that the company is unveiling several enhancements to its CyberKnife® Robotic Radiosurgery System and TomoTherapy® Radiation Therapy System as well as rolling out its Diamond Plus Service Program to TomoTherapy customers* at The American Society for Radiation Oncology (ASTRO) 53rd Annual Meeting. For the first time since the acquisition of TomoTherapy earlier this year, Accuray is showcasing both systems side-by-side in booth #225, demonstrating the full breadth and depth of the company's advanced, personalized radiation treatment capabilities and services. ASTRO takes place October 2-6, 2011 at the Miami Beach Convention Center in Miami, Fla.
Driven by the desire to create personalized solutions for each radiation oncology patient, Accuray has brought together the industry's leading-edge radiosurgery/stereotactic body radiotherapy (SRS/SBRT) and daily image-guided intensity modulated radiation therapy (IMRT) technologies. Together, the CyberKnife System, with real-time tracking and automatic correction and the ability to treat patients from hundreds of different angles, and the TomoTherapy System, which enables daily CT quality image-guided IMRT in a completely integrated treatment solution, provide practitioners with the capabilities, accuracy and flexibility needed to personalize and tailor radiation treatment for each patient.
"With the CyberKnife and TomoTherapy Systems under one roof, Accuray is able to provide a treatment option for nearly every patient —from the treatment of small, early-stage and localized lesions to large, complex and metastasized disease," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "Global customer adoption, coupled with a growing body of clinical evidence supporting use for an expanding number of indications, make CyberKnife and TomoTherapy truly leading-edge solutions for radiation oncology."
In its booth, Accuray will showcase several new product enhancements for both the CyberKnife and TomoTherapy Systems. These innovations include:
- CyberKnife Lung Optimized Treatment - an improved second generation suite of lung simulation and treatment products provides an optimum fiducial-free treatment option for every lung SBRT patient – regardless of tumor location.
- CyberKnife Xsight® Spine Prone - in combination with the Synchrony® Respiratory Tracking System, this new tracking product enables clinicians to deliver accurate, non-invasive spine radiosurgery to patients in the prone position to maximize sparing of the spinal cord and other surrounding tissues.
- TomoTherapy OIS Connect™ & CyberKnife Radiosurgery DICOM Interface - Integrates Accuray Treatment Systems with the oncology department's ARIA® and MOSAIQ® Oncology Information Systems, streamlining workflow and improving operational efficiency.
- TomoTherapy Hi·Art® V4.1 / TomoHD™ V1.1- The latest versions of the TomoTherapy System software, which include enhancements that improve clinical workflow and efficiency throughout the TomoTherapy process – from treatment planning to delivery.
- TomoTherapy Remote Software Solutions - Provides the power to develop more TomoTherapy treatment plans, from more places. This remote access solution is flexible, economical and secure and helps treatment centers using TomoTherapy treatment systems to retain the services of staff who need to live or work remotely.
In addition to the product enhancements, Accuray will now be extending its Diamond Plus Service Program to TomoTherapy customers. Unlike traditional service plans—which provide basic break/fix protection—Accuray's Diamond Plus Service Program includes upgrade protection and guaranteed uptime, ensuring that its systems are in optimal condition to provide world-class patient care. Now, TomoTherapy customers can benefit from the full spectrum of unparalleled service programs that CyberKnife customers have come to rely on.
Continuing the expansion of clinical evidence for both the CyberKnife and TomoTherapy Systems, more than 100 presentations on experience with the systems will be presented as part of the ASTRO scientific program. In particular, ASTRO will be highlighting a poster on 136 patients treated with CyberKnife prostate SBRT from Dr. Jonathan Haas at Winthrop-University Hospital as part of the "ARRO (Association of Residents in Radiation Oncology) Poster Walk with a Professor." Median follow-up in this study is 24 months with follow-up extending beyond 48 months for some patients. No recurrences or failures were noted to date within the 136 patients in the study. For a complete list of abstracts, please visit www.accuraymiami2011.com.
Finally, Accuray will host a symposium in the ASTRO Industry Expert Theater—titled "The Future of Radiation Oncology: Personalized Treatments"—examining the latest advances, research and data on stereotactic body radiation therapy (SBRT) and intensity-modulated radiation therapy (IMRT) in prostate cancer treatment. Chaired by Euan Thomson, Symposium speakers will include: Alan Katz, M.D., JD, radiation oncologist at Flushing Radiation Oncology in Flushing, New York, and Daniel Low, Ph.D., DABMP, professor and vice chair of physics at the University of California in Los Angeles, California. The Symposium will take place on Monday, October 3, 2011 from 12:15 p.m. – 1:30 p.m. in Hall C of the exhibit floor.
*Currently only available in the U.S.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company's technologies and more than 582 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical applications, clinical experience, clinical outcomes, number of patients treated and market acceptance of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2011 fiscal year filed on September 19, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
SOURCE Accuray Incorporated